A comparison of the pharmacokinetics of Aspen Ceftriaxone and Rocephin in community-acquired meningitis
BACKGROUND: Community-acquired bacterial meningitis (CABM) is a life-threatening condition that is common among immunocompromised individuals. Intravenous ceftriaxone, of which Rocephin (ROC) is the originator brand, is recommended as first-line therapy in South Africa. Despite concerns regarding therapeutic equivalence with generic agents, this is the first study that has been conducted comparing clinical pharmacokinetics (PK) of a generic ceftriaxone formulation with the originator. OBJECTIVE: To compare the PK and safety of Aspen Ceftriaxone (AC) and ROC in the treatment of adult CABM. METHODS: A total of 63 eligible patients were randomised 1:1 to receive 2 g of either medication twice daily for a duration based on the identity of the causative organism and their physician's clinical judgment. The primary endpoint of this study was the comparison of clinical PK, specifically the concentrations of each drug in the cerebrospinal fluid with corresponding paired plasma samples. While this study was underpowered to assess efficacy, safety could be evaluated on the basis of reported adverse events. RESULTS: The two patient groups were epidemiologically similar. There were no statistically significant differences in PK between either agent, nor any difference with regard to safety. CONCLUSION: AC can be considered as equivalent to ROC with regard to PK and safety in patients with CABM.
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
South African Medical Association
2013
|
Online Access: | http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S0256-95742013001200020 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0256-95742013001200020 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0256-957420130012000202014-02-19A comparison of the pharmacokinetics of Aspen Ceftriaxone and Rocephin in community-acquired meningitisRichards,G AElliott,EShaddock,E JMushi,DMzileni,MRay,RRulisa,SSeolwane,FStacey,S LStolz,AVenturas,J PSchoeman,HBACKGROUND: Community-acquired bacterial meningitis (CABM) is a life-threatening condition that is common among immunocompromised individuals. Intravenous ceftriaxone, of which Rocephin (ROC) is the originator brand, is recommended as first-line therapy in South Africa. Despite concerns regarding therapeutic equivalence with generic agents, this is the first study that has been conducted comparing clinical pharmacokinetics (PK) of a generic ceftriaxone formulation with the originator. OBJECTIVE: To compare the PK and safety of Aspen Ceftriaxone (AC) and ROC in the treatment of adult CABM. METHODS: A total of 63 eligible patients were randomised 1:1 to receive 2 g of either medication twice daily for a duration based on the identity of the causative organism and their physician's clinical judgment. The primary endpoint of this study was the comparison of clinical PK, specifically the concentrations of each drug in the cerebrospinal fluid with corresponding paired plasma samples. While this study was underpowered to assess efficacy, safety could be evaluated on the basis of reported adverse events. RESULTS: The two patient groups were epidemiologically similar. There were no statistically significant differences in PK between either agent, nor any difference with regard to safety. CONCLUSION: AC can be considered as equivalent to ROC with regard to PK and safety in patients with CABM.South African Medical AssociationSAMJ: South African Medical Journal v.103 n.12 20132013-12-01journal articletext/htmlhttp://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S0256-95742013001200020en |
institution |
SCIELO |
collection |
OJS |
country |
Sudáfrica |
countrycode |
ZA |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-za |
tag |
revista |
region |
África del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Richards,G A Elliott,E Shaddock,E J Mushi,D Mzileni,M Ray,R Rulisa,S Seolwane,F Stacey,S L Stolz,A Venturas,J P Schoeman,H |
spellingShingle |
Richards,G A Elliott,E Shaddock,E J Mushi,D Mzileni,M Ray,R Rulisa,S Seolwane,F Stacey,S L Stolz,A Venturas,J P Schoeman,H A comparison of the pharmacokinetics of Aspen Ceftriaxone and Rocephin in community-acquired meningitis |
author_facet |
Richards,G A Elliott,E Shaddock,E J Mushi,D Mzileni,M Ray,R Rulisa,S Seolwane,F Stacey,S L Stolz,A Venturas,J P Schoeman,H |
author_sort |
Richards,G A |
title |
A comparison of the pharmacokinetics of Aspen Ceftriaxone and Rocephin in community-acquired meningitis |
title_short |
A comparison of the pharmacokinetics of Aspen Ceftriaxone and Rocephin in community-acquired meningitis |
title_full |
A comparison of the pharmacokinetics of Aspen Ceftriaxone and Rocephin in community-acquired meningitis |
title_fullStr |
A comparison of the pharmacokinetics of Aspen Ceftriaxone and Rocephin in community-acquired meningitis |
title_full_unstemmed |
A comparison of the pharmacokinetics of Aspen Ceftriaxone and Rocephin in community-acquired meningitis |
title_sort |
comparison of the pharmacokinetics of aspen ceftriaxone and rocephin in community-acquired meningitis |
description |
BACKGROUND: Community-acquired bacterial meningitis (CABM) is a life-threatening condition that is common among immunocompromised individuals. Intravenous ceftriaxone, of which Rocephin (ROC) is the originator brand, is recommended as first-line therapy in South Africa. Despite concerns regarding therapeutic equivalence with generic agents, this is the first study that has been conducted comparing clinical pharmacokinetics (PK) of a generic ceftriaxone formulation with the originator. OBJECTIVE: To compare the PK and safety of Aspen Ceftriaxone (AC) and ROC in the treatment of adult CABM. METHODS: A total of 63 eligible patients were randomised 1:1 to receive 2 g of either medication twice daily for a duration based on the identity of the causative organism and their physician's clinical judgment. The primary endpoint of this study was the comparison of clinical PK, specifically the concentrations of each drug in the cerebrospinal fluid with corresponding paired plasma samples. While this study was underpowered to assess efficacy, safety could be evaluated on the basis of reported adverse events. RESULTS: The two patient groups were epidemiologically similar. There were no statistically significant differences in PK between either agent, nor any difference with regard to safety. CONCLUSION: AC can be considered as equivalent to ROC with regard to PK and safety in patients with CABM. |
publisher |
South African Medical Association |
publishDate |
2013 |
url |
http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S0256-95742013001200020 |
work_keys_str_mv |
AT richardsga acomparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT elliotte acomparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT shaddockej acomparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT mushid acomparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT mzilenim acomparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT rayr acomparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT rulisas acomparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT seolwanef acomparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT staceysl acomparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT stolza acomparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT venturasjp acomparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT schoemanh acomparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT richardsga comparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT elliotte comparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT shaddockej comparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT mushid comparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT mzilenim comparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT rayr comparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT rulisas comparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT seolwanef comparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT staceysl comparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT stolza comparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT venturasjp comparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis AT schoemanh comparisonofthepharmacokineticsofaspenceftriaxoneandrocephinincommunityacquiredmeningitis |
_version_ |
1756005662764040192 |